Keyuan Pharmaceutical (301281.SZ) released its performance for the first three quarters, with net profit attributable to the parent company of 85.3435 million yuan, a year-on-year increase of 171.18%.

Zhitong Finance APP News, Keyuan Pharmaceutical (301281.SZ) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 483 million yuan, a year-on-year increase of 59.42%; net profit attributable to shareholders of the listed company was 85.3435 million yuan, a year-on-year increase of 171.18%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 75.1633 million yuan, a year-on-year increase of 231.90%; basic earnings per share were 0.7881 yuan. The company's revenue growth was mainly due to an increase in sales of new formulation products during the reporting period.